<DOC>
	<DOCNO>NCT03070119</DOCNO>
	<brief_summary>The primary objective study evaluate long-term safety tolerability BIIB067 participant Amyotrophic Lateral Sclerosis Caused Superoxide Dismutase 1 Mutation ( SOD1-ALS ) . The secondary objective evaluate pharmacokinetic ( PK ) profile BIIB067 participants SOD1-ALS .</brief_summary>
	<brief_title>Long-Term Evaluation BIIB067</brief_title>
	<detailed_description />
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Superoxide Dismutase</mesh_term>
	<criteria>Key Must diagnosis SOD1ALS , must complete Part A and/or Part B Study 233AS101 ( NCT02623699 ) ( i.e. , withdraw miss 1 dose study drug ) . If taking riluzole , must receive stable dose â‰¥30 day prior Day 1 expect remain dose final study visit . For participant childbearing potential must agree practice effective contraception study 5 month last dose study treatment . Medically able undergo study procedure , adhere visit schedule time study entry , determine Investigator . Key History positive test result human immunodeficiency virus . History positive test result hepatitis C virus antibody hepatitis B virus ( define positive hepatitis B surface antigen hepatitis B core antibody ) . History allergy broad range anesthetic . Presence risk increase uncontrolled bleeding and/or risk bleed manage optimally could place participant increase risk bleed Lumbar Puncture ( LP ) procedure . These risk could include , limited , anatomical factor near LP site ( e.g. , vascular abnormality , neoplasm , abnormality ) underlie disorder coagulation cascade , platelet function , platelet count ( e.g. , hemophilia , Von Willebrand 's disease , liver disease ) . Presence implant shunt drainage CSF implanted central nervous system ( CNS ) catheter . Prior current treatment small interfering ribonucleic acid ( RNA ) , stem cell therapy , gene therapy . Treatment another investigational drug , biological agent ( exclude BIIB067 ) , device within 1 month 5 halflives study agent , whichever longer . Current anticipate need , opinion Investigator , diaphragm pacing system ( DPS ) study period . Female participant pregnant currently breastfeed . Current enrollment interventional study . Current recent ( within 1 month ) use , anticipate need , opinion Investigator , copper ( II ) ( diacetylbis ( N4methylthiosemicarbazone ) ) pyrimethamine . NOTE : Other protocol define Inclusion/Exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>